Short Interest in Aadi Bioscience, Inc. (NASDAQ:AADI) Expands By 49.4%

Aadi Bioscience, Inc. (NASDAQ:AADI) saw a large increase in short interest in January. As of January 31st, there was short interest totalling 706,400 shares, an increase of 49.4% from the January 15th total of 472,700 shares. Based on an average daily trading volume, of 357,800 shares, the short-interest ratio is presently 2.0 days. Approximately 3.5% of the shares of the stock are short sold.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. XTX Topco Ltd purchased a new stake in shares of Aadi Bioscience in the 3rd quarter valued at $32,000. Geode Capital Management LLC lifted its stake in Aadi Bioscience by 4.1% in the fourth quarter. Geode Capital Management LLC now owns 217,294 shares of the company’s stock worth $686,000 after purchasing an additional 8,546 shares during the last quarter. Peapod Lane Capital LLC purchased a new stake in Aadi Bioscience during the fourth quarter valued at about $1,397,000. Finally, BML Capital Management LLC bought a new position in shares of Aadi Bioscience during the third quarter valued at about $4,120,000. 52.08% of the stock is owned by hedge funds and other institutional investors.

Aadi Bioscience Price Performance

NASDAQ:AADI opened at $2.61 on Friday. The company has a market capitalization of $64.47 million, a price-to-earnings ratio of -1.14 and a beta of 0.64. The business has a 50 day moving average of $2.91 and a 200 day moving average of $2.25. Aadi Bioscience has a 1-year low of $1.21 and a 1-year high of $3.81.

Aadi Bioscience Company Profile

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.